In the first half of the year, the FDA approved a number of landmark drugs, and there are many highlights: Rezdiffra, the first non-alcoholic steatohepatitis drug in 40 years, was […]
In the first half of the year, the FDA approved a number of landmark drugs, and there are many highlights: Rezdiffra, the first non-alcoholic steatohepatitis drug in 40 years, was […]